Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer

Launched by SUNNYBROOK HEALTH SCIENCES CENTRE · Oct 26, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to treat prostate cancer using a technique called stereotactic ablative body radiotherapy (SABR). SABR delivers radiation precisely to the cancer, and this study aims to compare a shorter treatment plan of just two sessions over two weeks to the standard five sessions that are typically given. Researchers want to see if the shorter treatment is just as effective in controlling the cancer while also improving the quality of life for patients, particularly in terms of sexual health.

To be eligible for this trial, men aged 65 to 74 with a confirmed diagnosis of prostate cancer that is classified as low or favorable intermediate risk can participate. This means that their cancer is at a stage where it has a better chance of being treated effectively. Participants will receive either the two-session treatment or the standard five-session treatment, and they will be monitored closely throughout the process. It’s important to note that certain health conditions or treatments, like prior radiation therapy or specific medications, may prevent someone from joining the trial. Overall, this study aims to provide valuable information that could lead to more effective and convenient treatment options for prostate cancer patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed prostate adenocarcinoma (centrally reviewed)
• 2. Low or favorable intermediate risk disease. Patient must meet one of the following categories:
• • Low risk - T1-T2b, grade group 1, AND PSA \< 10 ng/ml;
• • Favorable risk
• • 1. Only one of the following intermediate risk factors - cT2c, grade group 2, or PSA 10-20 ng/ml; or
• • 2. Grade group 3 AND PSA \< 20, AND \<cT2c AND absolute percentage pattern 4/5 is \<10%
• Exclusion Criteria:
• • 1. Androgen deprivation therapy (LHRH-agonists or antiandrogens) given or planned
• • 2. Prior pelvic radiotherapy
• • 3. Anticoagulation medication (if unsafe to discontinue for gold seed insertion)
• • 4. Diagnosis of bleeding diathesis
• • 5. Large prostate (\>90cm3) on imaging
• • 6. Immunosuppressive medications
• • 7. Inflammatory bowel disease
• • 8. Presence of dual hip prostheses
• • 9. Contraindications to having MRI